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Absence of dystrophin makes skeletal muscle more susceptible to injury,
resulting in breaches of the plasma membrane and chronic inflammation in
Duchenne muscular dystrophy (DMD). Current management by glucocorticoids
has unclear molecular benefits and harsh side effects. It is uncertain whether
therapies that avoid hormonal stunting of growth and development, and/or
immunosuppression, would be more or less beneficial. Here, we discover an oral
drug with mechanisms that provide efficacy through anti-inflammatory
signaling and membrane-stabilizing pathways, independent of hormonal or
immunosuppressive effects. We find VBP15 protects and promotes efficient
repair of skeletal muscle cells upon laser injury, in opposition to prednisolone.
Potent inhibition of NF-kB is mediated through protein interactions of the
glucocorticoid receptor, however VBP15 shows significantly reduced hormonal
receptor transcriptional activity. The translation of these drug mechanisms into
DMD model mice improves muscle strength, live-imaging and pathology through
both preventive and post-onset intervention regimens. These data demonstrate
successful improvement of dystrophy independent of hormonal, growth, or
immunosuppressive effects, indicating VBP15 merits clinical investigation for
DMD and would benefit other chronic inflammatory diseases.
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INTRODUCTION
Contraction‐induced myoﬁbre injury and inﬂammation are
characteristic features of Duchenne muscular dystrophy
(DMD), a fatal genetic muscle disease. We and others have
demonstrated that the pro‐inﬂammatory transcription factor NF‐
kB is active in dystrophin deﬁcient muscle before symptom onset
(Chen et al, 2005; Porter et al, 2002, 2003). Pharmacological
glucocorticoids (prednisone, deﬂazacort) are standard of care in
DMD, and we hypothesize their primary mechanism of action to
be through anti‐inﬂammatory activities via NF‐kB pathways
(Wissink et al, 1997). However, their harsh side effects in
children greatly reduce patient adherence to glucocorticoid
regimens and limit their therapeutic window. More general
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immunosuppressive compounds reduce inﬂammation in DMD
but fail to increase patient strength in the same manner as
glucocorticoids (Griggs et al, 1993; Kissel et al, 1993), while
speciﬁc targeting of NF‐kB increases strength in animal models
(Grounds & Torrisi, 2004; Peterson et al, 2011). These data suggest
that the speciﬁc mechanism by which glucocorticoids inhibit
NF‐kB is of particular importance to DMD treatment efﬁcacy.
Therapeutics that target this pathway in the absence of side effects
may provide a substantial improvement in the treatment of DMD.
At the cellular level, dystrophin deﬁcient muscles show
increased susceptibility to stretch‐mediated membrane instability and calcium dependent hyper‐contracture (Bertorini
et al, 1982; Yasuda et al, 2005), as well as increased oxidative
stress (Disatnik et al, 1998; Rando et al, 1998). Glucocorticoids
and other steroidal compounds are multi‐mechanistic; in
addition to binding hormonal receptors they can interact with
the plasma membrane to exert rapid and speciﬁc physicochemical effects (Buttgereit et al, 1999; Lipworth, 2000; Rhen
et al, 2003; Shivaji & Jagannadham, 1992). These effects can alter
membrane ﬂuidity, vesicular fusion (Shivaji & Jagannadham,
1992) and ionic ﬂux (Buttgereit et al, 1999), which are important
for resistance to and repair of membrane injury. Recently,
membrane stabilizing compounds such as poloxamer 188
(Spurney et al, 2011; Townsend et al, 2010), Mitsugumin 53
(Burkin & Wuebbles, 2012; Weisleder et al, 2012) and cromolyn
sodium (Granchelli et al, 1996; Marques et al, 2008) have
shown improvements to pathology, myoﬁbre tension and
cardiopulmonary function in dystrophin‐deﬁcient mice and
dogs. The effects of glucocorticoids on membrane stability,
however, have not been reported.
Because glucocorticoids act through multiple mechanisms,
it has been unclear and controversial which molecular
pathways provide efﬁcacy in DMD and which are simply
responsible for detrimental effects. For example, impaired
growth is a glucocorticoid side effect for children with asthma
(Avioli, 1993; Wolthers & Pedersen, 1990), but has been
proposed as a pathway of efﬁcacy in DMD by limiting muscle
workload and delaying muscle maturation (Grounds &
Shavlakadze, 2011). Further, immunotoxic effects contribute
to reduced chronic inﬂammation, but recent evidence suggests
ant‐inﬂammatory NF‐kB inhibition may be sufﬁcient for efﬁcacy
(Peterson et al, 2011). It is clear, however, that detrimental
effects of glucocorticoids currently limit their application; in
DMD neonatal screening is not performed, and glucocorticoid
regimens are delayed years until after the onset of fairly
advanced symptoms. In other forms of muscular dystrophy,
glucocorticoids are avoided altogether because the net balance of
positive and negative effects is unclear. By investigating the
molecular mechanisms of glucocorticoids, we have developed
VBP15 as a novel oral drug. This compound is optimized for
NF‐kB inhibition, membrane insertion and glucocorticoid
receptor (GR) speciﬁcity. Medicinal chemistry, however, both
eliminates key glucocorticoid pathways and provides novel
properties. Here, we present the discovery and mechanisms of
this drug, then extensively examine efﬁcacy and side effects in
mdx muscular dystrophy model mice. We ﬁnd VBP15 has novel
membrane‐stabilizing and immunological properties, and shows
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potent NF‐kB inhibition and substantially reduced hormonal
effects. To capitalize on this mechanism proﬁle, which targets
multiple pre‐symptomatic defects, we adopt a prophylactic
regimen, beginning dosing before mdx symptom onset in a
blinded pre‐clinical trial. This strategy would be analogous to a
neonatal screening, preventive regimen in the clinic. Another
intervention experiment in post‐onset adult mdx mice shows
repeatable efﬁcacy in a different stage of disease. We ﬁnd dose–
response improvements with successful ablation of growth,
bone and immunological toxicities seen with traditional
glucocorticoids. These data provide new insights into biological
mechanisms of efﬁcacy versus side effects in DMD, identify
VBP15 as a novel entity that warrants clinical investigation for
DMD, and show therapeutic potential for other disorders of
chronic inﬂammation and membrane instability.

RESULTS
In vitro characterization of VBP15
VBP15 was selected as our lead compound for clinical
development from a screening program focused on D‐9,11
compounds. This D‐9,11 class is differentiated from glucocorticoids by the key conversion of a hydroxyl group to a carbon‐
carbon double bond (Fig 1). Preliminary studies suggested these
drugs had potential anti‐inﬂammatory effects (Baudy et al, 2012)
but lacked activation of a synthetic GR reporter. Through
extensive medicinal chemistry probing the R1–R3 groups of the
D‐ring in this steroidal structure to generate a compound library,
followed by multiple lines of screening studies focused on 20
candidates, VBP15 was subsequently identiﬁed as our lead
compound. Selection was based upon its superior proﬁle in an in
vitro assay for NF‐kB inhibition in myogenic cells, in addition to
ligand‐induced nuclear translocation of the GR, cytotoxicity,
metabolite and pharmacokinetic properties (Reeves et al, 2013).
To further screen candidate compounds for target receptor
speciﬁcity, we performed competitive nuclear hormone receptor
binding assays (Fig 1E–H). In these assays, we found that VBP15
shows increased speciﬁcity for GR binding in comparison to
other D‐9,11 compounds. For example, VBP15 exhibited an
approximately 50‐fold greater afﬁnity for the GR than VBP3, and
a 64‐fold lower afﬁnity for the mineralocorticoid receptor (MR).
VBP15 also showed only very low afﬁnity for the androgen
receptor (Fig 1G), over 500‐fold lower than the control
methyltrienolone, and lacked any detectable binding to the
oestrogen (Fig 1H) or progesterone (data not shown) receptors
in these in vitro assays. From these screening, biochemical
and speciﬁcity data, VBP15 presented a superior proﬁle for
therapeutic development.
Our studies here are benchmarked against prednisolone, the
active form of prednisone. Both VBP15 and prednisolone
inhibited TNFa‐induced pro‐inﬂammatory NF‐kB signaling at
similar levels in NF‐kB reporter assays in C2C12 muscle cells at
1 nM or more (Fig 2A). To conﬁrm effects on NF‐kB target genes,
several inﬂammatory transcripts known to be induced by TNFa
were assayed by qPCR in VBP15‐ and prednisolone‐treated
H2K myotubes. We found VBP15 inhibited the TNFa‐induced
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Figure 1. VBP15 structure differentiates it from glucocorticoids and improves GR speciﬁcity.
A–D. The chemical structure of VBP15 is provided (A). VBP15 was selected for clinical development by having the optimal profile from a library of D-9,11
compounds, whose general structure is provided in (B). Compound diversity for this library was generated by medicinal chemistry probing of the R1–R3
groups. These compounds are structurally related to glucocorticoids (C), but contain an essential D-9,11 double bond modification to the steroid C-ring, at
the location depicted by the red box. This modification produces novel properties and clear differences in sub-activity profiles of these compounds.
Prednisolone (D) is the active form of prednisone, a current glucocorticoid standard of care for DMD.
E–H. Receptor specificity was determined through competitive binding assays. Here, radiolabeled high-affinity ligands were incubated with extracted steroid
receptors and increasing concentrations of unlabeled competitor (high-affinity control, VBP15, VBP1 or VBP3). Best-fit curves are provided. VBP15 showed
increased GR specificity through increased binding to the (E) GR and decreased binding to the (F) MR in comparison to other D-9,11 compounds (VBP1 and
VBP3). VBP15 also showed low (H) androgen receptor binding and no detectable binding to the (G) oestrogen receptor. (Triam, triamcinolone; Spiro,
spironolactone; R1881, methyltrienolone; Estradiol, 17b-estradiol).

inﬂammatory transcripts Cox2, Irf1 and Nos2 (p < 0.005) at
potencies similar to prednisolone (Fig 2B).
Both prednisolone and VBP15 are hydrophobic compounds
that are expected to have physicochemical effects on lipid
bilayers. We compared the effects of VBP15 and prednisolone on
membrane injury and repair in live cells using an established
laser injury assay (Sharma et al, 2012). Skeletal muscle cells
treated with VBP15 showed reduced impact of the injury and
enhanced repair in a dose dependent fashion (Fig 2C and D).
Cells treated with prednisolone, however, showed greater
impact from injury with elevated dye uptake. In this live
single‐cell injury model, prednisolone exacerbated, while VBP15
protected, injury to the plasma membrane.
GR mediates VBP15 anti‐inﬂammatory effects without
inducing classical steroid transactivation
To investigate whether NF‐kB inhibition by VBP15 is mediated
by the same pathways as glucocorticoids, we examined the
effects of the steroidal receptor antagonist, RU‐486, on NF‐kB
inhibition. Increasing concentrations of RU‐486 from 1 nM to
10 mM ablated NF‐kB inhibition by VBP15 in a dose dependent
manner, similar to results seen with prednisolone and
dexamethasone (Fig 3A). This shows that the anti‐inﬂammatory
effects of VBP15, prednisolone and dexamethasone are all
mediated through shared steroidal pathways.

EMBO Mol Med (2013) 5, 1569–1585

A sub‐activity of pharmacologic glucocorticoids that is largely
separable from NF‐kB inhibitor activities is the translocation of
ligand‐GR complexes to the nucleus where they directly mediate
transcriptional pathways via glucocorticoid response elements
(GRE) (e.g. classical steroid receptor transactivation or hormonal properties). Both positive‐ and negative‐acting GRE‐mediated
transcriptional regulation has been described, and both forms
of hormonal activities are more often associated with glucocorticoid side effects rather than efﬁcacy, with some of these
mediated by the pituitary (Diamond et al, 1990; Drouin
et al, 1993; Itani et al, 2002; Meijsing et al, 2009; Yoshiuchi
et al, 1998). In AtT‐20 pituitary cells, we examined genes
regulated by positive and negative GREs. Sgk1, a key mediator of
ﬁbrosis, is activated by a positive GRE. Both prednisone and
dexamethasone (0.1 mM) showed a greater than 13‐fold
induction of Sgk1 gene transcription, whereas VBP15 showed
no such GRE‐mediated transcriptional activity at the same
concentration (Fig 3B). At 1.0 and 10 mM, VBP15 began to show
some evidence of Sgk1 transcriptional induction, but to a lower
degree than traditional glucocorticoids. Adrenocorticotropic
hormone (ACTH), the stimulatory hormone in adrenal steroidogenesis, is negatively regulated by a ligand/GR‐GRE interaction
(Drouin et al, 1993). Treatment with dexamethasone or
prednisolone reduced ACTH secretion in AtT‐20 cells to
approximately 20% of untreated at all concentrations tested

ß 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.
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Figure 2. VBP15 inhibits inﬂammatory signaling and promotes membrane
stability.
A. In an NF-kB reporter assay, increasing concentrations of prednisolone or
VBP15 were applied to TNFa-induced C2C12 myoblasts stably
expressing a luciferase reporter under the control of an NF-kB driven
promoter. Significant reporter inhibition was observed at all concentrations over 10 nM.
B. Inhibition was also observed for endogenous NF-kB activated inflammatory transcripts. Cox2, Irf1 and Nos2 expression was significantly
reduced in TNFa-induced H2K myotubes, as determined by real time
qPCR. Results are mean  SEM from representative experiments
performed in triplicate (ANOVA,  p < 0.05,   p < 0.005,    p < 0.0005).
C,D. Laser injury and dye exclusion assays to determine effects of VBP15 and
prednisolone on cell membrane integrity. (C) Images of C2C12 myoblasts
exposed to the indicated drug 15 min prior to laser wounding, with
fluorescent visualization of FM1-43 dye entry into cells (white
arrowheads mark sites of injury, scale bars ¼ 5 mm). VBP15 shows
protection against laser-induced injury. (D) Quantitation of FM1-43
influx over time (laser injury at time 6 s). VBP15 shows reduced impact of
initial injury and enhanced repair, whereas prednisolone shows greater
impact from injury with elevated dye uptake. Representative data from
one of four experiments are presented as mean  SEM. (ANOVA, n  16
per treatment,  p < 0.05; Pred, prednisolone).

(Fig 3C). VBP15 produced more modest, dose‐dependent effects
on ACTH. qPCR of Pomc, the ACTH precursor, conﬁrmed effects
were consistent with transcription (data not shown). Thus,
VBP15 has greatly reduced effects on both positively and
negatively GRE‐regulated transcripts in comparison to glucocorticoids, and might be expected to show a more favourable
side effect proﬁle.
Several mechanisms have been hypothesized for the inhibition of NF‐kB by glucocorticoids and the GR. These include
GRE‐driven transactivation of genes that inhibit NF‐kB, direct
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protein–protein interactions through which the GR may act
as a corepressor when bound to NF‐kB, and the activation
of alternative receptors such as the MR. To investigate the
mechanism by which glucocorticoids, VBP15 and/or the
activated GR inhibit NF‐kB, we performed further experiments
in GR mutant cells. First, we tested whether the lack of GR in
GRnull mutant ﬁbroblasts affects the ability of drugs to inhibit
inﬂammatory transcripts, which are predominantly controlled
by NF‐kB. Absence of the GR in this spontaneous mutant line
was previously selected for (Housley & Forsthoefel, 1989) and
conﬁrmed here through Western blot (Fig 3D). Cells were then
treated with prednisolone or VBP15 and inﬂammatory transcripts were induced with TNFa. Ablation of GR transactivation
functions in GRnull cells was conﬁrmed through qPCR of Sgk1
transcript levels (Fig 3E). Examining inﬂammatory transcripts,
we found Irf1 (p < 0.0001), Tnfa (p < 0.05) and Il1a (p < 0.05)
expression to all be signiﬁcantly elevated in induced versus non‐
induced cells. In GR positive cells, both VBP15 and prednisolone
inhibited the induction of Irf1 (p < 0.005), Tnfa (p < 0.01) and
Il1a (p < 0.05) to levels that were 30–58% of vehicle (Fig. 3F). In
GRnull cells, neither drug was able to inhibit the induction of any
of these transcripts. This data conﬁrms that ligand‐activated GR
is essential for the inhibition of predominantly NF‐kB driven
inﬂammatory transcripts by both prednisolone and VBP15.
Next, primary splenocytes were harvested from control and
GRdim mutant mice. These mice contain a mutation in the
DNA binding domain of the GR (Dahlman‐Wright et al, 1991;
Reichardt et al, 1998). This mutation prevents the GR from
binding to DNA and activating dimer‐driven GRE gene
transcription, but maintains GR ligand‐binding and protein–
protein interactions. Here, primary splenocytes were treated
with drug and induced with TNFa, then assayed by qPCR. First,
we examined the induction of NF‐kB inhibitor alpha (Nfkbia, or
IkBa), a GRE‐activated gene that also encodes an endogenous
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Figure 3. GR is required for anti‐inﬂammatory activities of VBP15 and prednisolone, but VBP15 shows loss of GRE‐mediated sub‐activities associated with
side effects.
A. Application of a steroidal receptor antagonist (RU-486) ablated the NF-kB inhibitory activity of both prednisolone and VBP15, indicating that both drugs
share steroidal anti-inflammatory pathways.
B,C. Assessment of GRE-mediated transcriptional (hormonal) activities differentiates prednisolone and VBP15. (B) Sgk1 gene expression is controlled by a
positive GRE and showed reduced activation by VBP15 in comparison to glucocorticoids in AtT-20 pituitary cells, as measured by qRT-PCR. a-Tocopherol was
included as a negative control compound that lacks any GRE activity. (C) ACTH expression is controlled by a negative GRE, and is considered a component of
adrenal suppression (negative side effect of pharmacological glucocorticoids). VBP15 showed reduced effects on this side effect pathway via ELISA of treated
AtT-20 cell media.
D. Western blot of GRnull fibroblasts and the control GR positive L929 line they were derived from, illustrating the absence of detectable GR protein in the GRnull
cells. GAPDH was included as a loading control.
E,F. GRnull and GR positive fibroblasts were treated with drug, then induced with TNFa and transcript levels assayed by real time qPCR. (E) Sgk1 levels illustrate an
absence of induction in GRnull cells, confirming Sgk1 dependence on the GR and the absence of GR function in this cell line. (F) Inhibition of the endogenous
NF-kB activated inflammatory transcripts Irf1, Tnfa and Il1a was observed in GR positive cells but not in GRnull cells, indicating the GR is essential for this
inhibition.
G,H. Spleens were harvested from GRdim/dim and wild type control mice. Splenocyte suspensions were treated with drug, then induced with TNFa and transcripts
assayed by qPCR. (G) Nfkbia levels illustrate an absence of GRE induction by the mutant GR, as well as a lack of induction of NF-kB inhibiting gene products, in
GRdim/dim splenocytes. (H) Inhibition of Irf1, Tnfa and Il6 inflammatory transcripts was observed in both wild type and GRdim/dim mutant splenocytes. This
indicates GRdim isoforms, which maintain protein-protein interactions but lose receptor-DNA interactions, still maintain inhibition of endogenous NF-kB
activated inflammatory transcripts. (Pred, prednisolone; Dex, dexamethasone; a-Toc, vitamin E; ANOVA,  p < 0.05,   p < 0.005,    p < 0.0005).

inhibitor of NF‐kB. In wild type control splenocytes, Nfkbia
expression was signiﬁcantly increased by prednisolone (increase
of 45  13%, p < 0.005) but not by VBP15 (increase of 16  16%)
in comparison to vehicle. No induction was present with either

EMBO Mol Med (2013) 5, 1569–1585

drug in GRdim splenocytes, demonstrating both the absence of
GR dimer‐driven gene expression in GR dim cells and a lack of
induction of NF‐kB inhibitory genes. Examining inﬂammatory
transcripts, we found Irf1 (p < 0.0001), Tnfa (p < 0.0001) and Il6
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(p < 0.05) were signiﬁcantly elevated within induced versus
non‐induced primary splenocytes. Consistent with GR positive
ﬁbroblasts and H2K myotubes, treatment of wild type
splenocytes with both VBP15 and prednisolone successfully
inhibited the induction of all three inﬂammatory transcripts
(p < 0.001) to levels that were roughly half those of vehicle. In
contrast to GRnull genotype and GRE transcript experiments, we
found that inhibition of all three inﬂammatory transcripts was
maintained in the GRdim mutant cells. Together, these experiments show that both prednisolone and VBP15 activate the GR to
efﬁciently inhibit inﬂammatory transcription programs through
protein–protein interactions, independent of DNA binding or
transactivation of inhibitory genes.
VBP15 improves dystrophic phenotypes in mice treated before
the onset of early necrosis
The mdx mouse model of DMD shows staged histopathology,
with little evidence of dystrophy from 0 to 3 weeks of age, then
wide‐spread necrosis from 3 to 6 weeks, followed by successful
regeneration and a milder, more stable histological picture. We
tested efﬁcacy of VBP15 in the mdx model with treatment
beginning prior to the 3 weeks onset of widespread pathology
(prophylactic strategy). We carried out a blinded pre‐clinical trial
of pre‐symptomatic mice with VBP15 (5, 15 or 30 mg/kg),
prednisolone (5 mg/kg), or vehicle beginning at postnatal day 15
(PND15), following guidelines for robust pre‐clinical trials
and international SOPs (Landis et al, 2012; Nagaraju &
Willmann, 2009; Spurney et al, 2009). These doses were chosen
on the basis of favourable bioavailability, ADME and metabolite
proﬁles (Reeves et al, 2013), as well as early safety studies in
wild type mice by independent groups, which suggest the 28 day
no‐observable adverse effect level (NOAEL) of daily oral VBP15
in mice is at least 100 mg/kg. This dose range was chosen to
better deﬁne the therapeutic window within this mouse disease
model. The prednisolone dose was chosen based on our
extensive pre‐clinical experience with this drug in the mdx
mouse model.
Both VBP15 and prednisolone increased mdx forelimb and
hindlimb normalized grip strength in comparison to vehicle
(Fig 4A and B). Signiﬁcant increases in VBP15 groups followed a
dose‐dependent pattern from 14% at 5 mg/kg (p < 0.05) to 20%
at 30 mg/kg (p < 0.0005). For maximal force exerted, we again
saw a dose dependent increase in forelimb strength upon VBP15
treatment, while prednisolone actually showed a reduction in
maximal forelimb strength (Fig 4C). The discrepancy between
prednisolone’s effects on maximal and normalized force
measures was due to the marked retardation of mouse growth
induced by prednisolone, but not by VBP15 (see below). This
indicates VBP15 increases functional mouse limb strength.
Evaluating muscle strength of isolated muscles ex vivo,
extensor digitorum longus (EDL) muscles showed a reduction in
speciﬁc force for mdx compared to WT (Fig 4D). While
prednisolone showed no increase, speciﬁc force increased with
VBP15 at both 15 and 30 mg/kg by an average of 12%. Following
lengthening contractions, smaller drops in force for mdx EDLs
after 10 contractions were observed for mice treated with
prednisolone (7%) and VBP15 (11% at 15 mg/kg, p < 0.05), in
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comparison to vehicle (Supporting Information Fig 1A). These
data suggest functional beneﬁts to isolated dystrophic muscles.
Optical imaging of live animals was used to monitor muscle
inﬂammation. ProSense 680, a substrate cleaved by cathepsin
proteases upregulated in DMD (Kar & Pearson, 1978; Takeda
et al, 1992), was injected as previously reported (Baudy
et al, 2011). Cathepsin activity was elevated in mdx mice
(Fig 4E, Supporting Information Fig 1B and C). VBP15 and
prednisolone decreased cathepsin activity towards WT levels.
Decreases in VBP15 groups followed a dose‐dependent pattern,
from a 22% decrease in comparison to vehicle at 5 mg/kg to a
41% decrease at 30 mg/kg in hindlimbs. This suggests VBP15
reduces muscle inﬂammatory disease in vivo.
In histopathology studies, quantitative H&E analysis of mdx
diaphragms revealed a clear inﬂammatory phenotype, with
16‐fold higher inﬂammatory cell counts compared to WT
(Fig 4F). Mice treated with VBP15 at 15 and 30 mg/kg displayed
38 and 30% reductions in inﬂammatory foci compared to vehicle.
VBP15 also reduced calciﬁed ﬁbres (Supporting Information
Fig 1D). These data are evidence that VBP15 reduces inﬂammation and improves inﬂammatory muscle pathology.
VBP15 improves dystrophic phenotypes in adult mdx mice
treated after symptom onset
In a separate trial, exercised adult mdx mice were treated for
4 months. In agreement with the pre‐symptomatic trial above,
ProSense680 live animal imaging exhibited a 20% and 13%
decrease in muscle inﬂammation upon VBP15 treatment at 15
and 45 mg/kg (Fig 4G). Isolated EDLs showed a 16% increase in
speciﬁc force upon treatment with VBP15 at 15 mg/kg (Fig 4H).
H&E histology revealed VBP15 signiﬁcantly decreased diaphragm inﬂammation (Fig 4I). These data reinforce VBP15
efﬁcacy and indicate both pre‐symptomatic and post‐onset
treatment regimens can beneﬁt disease.
VBP15 does not display immunotoxicity seen with
prednisolone
Pharmacologic glucocorticoids show immunosuppressive and
immunotoxic properties that limit therapeutic windows and
long‐term prescription. We benchmarked VBP15 against
prednisolone to determine if similar sub‐activities were seen.
Untreated mdx mice showed enlarged spleens and increased
numbers of peripheral blood leucocytes (PBLs) compared to WT
mice (Supporting Information Fig 2A and B). VBP15 treatment
reduced spleen mass and PBL counts in a dose‐dependent
manner to levels resembling WT. Prednisolone reduced these
measures below WT, suggesting immunosuppressive and/or
immunotoxic properties. Further, prednisolone signiﬁcantly
decreased viable splenocytes per gram of tissue (p < 0.005),
while this was not observed for any VBP15 dose (Fig 5A).
We next examined effects of VBP15 on B and T lymphocytes
isolated from mdx spleens at the trial conclusion. Both B
lymphocytes and CD4þ T lymphocytes were depleted by
prednisolone but not VBP15, as measured by percent B220þ
and CD4þ positive splenocytes, respectively (Fig 5B and C). CD4þ
T cell activation was assayed by stimulation of splenocytes with
concanavalin A (ConA). Prednisolone treatment signiﬁcantly
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Figure 4. VBP15 improves dystrophic phenotypes of mdx mice in two pre‐clinical trials (pre‐symptomatic and post‐onset treatment regimens).
A–F. Prophylactic treatment of mdx mice beginning at 2 weeks of age showed dose-dependent improvement of clinical and histological endpoints. Mouse limb
strength increased upon VBP15 treatment as measured by grip strength of 6 week old mice for both (A) forelimb and (B) hindlimb (n  12 mice/group). (C)
Maximal force exerted by mouse forelimbs increased with VBP15 treatment but decreased with prednisolone treatment, due to prednisolone effects on
mouse size (presented later). (D) Specific force of isolated EDL muscle increased with VBP15 treatment (n ¼ 10 mice/group). (E) Live-animal imaging of
cathepsin protease activity (ProSense680) shows reduced inflammation and necrosis of the hindlimbs in VBP15-treated mdx mice (E images; E0 quantitation
of fluorescence; n  6 mice/group). (F) Histology of diaphragm muscle shows a decrease in inflammatory foci from VBP15 treatment at 15 and 30 mg/kg
(F representative images, F0 quantitation; n ¼ 6 mice/group).
G–I. A second pre-clinical trial was performed in exercised adult mdx mice to assay post-onset efficacy. (G) Live-animal imaging of inflammation (ProSense680)
showed a significant decrease with VBP15 treatment (G representative images, (G0 ) quantitation; n  6 mice/group). (H) Specific force of isolated EDL muscle
was measured ex vivo at trial conclusion with 15 mg/kg VBP15 showing an increase consistent with the neonate trial (n  7 mice/group). (I) Histology of adult
diaphragm showed a significant reduction in inflammatory foci upon 45 mg/kg VBP15 treatment (n ¼ 6 mice/group). Values are mean  SEM. For treatments,
the mean percentage of increase or decrease of mdx vehicle values towards WT is provided. (Pred, prednisolone; FL, forelimb; HL, hindlimb; data exceeding 2
SD’s was removed from specific force values as an outlier but included in all statistical analyses; one-tailed t-test of single dose versus vehicle mdx yp < 0.05;
ANOVA of dose-dependence groups versus vehicle mdx  p < 0.05,   p < 0.005,    p < 0.0005).
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Figure 5. VBP15 does not show immunosuppressive activities shown by
prednisolone.
A. Prednisolone significantly reduced the number of viable splenocytes per
gram of spleen tissue, whereas VBP15 did not at any dose.
B. The percentage of B lymphocytes, as measured by FACS analysis of B220
positive cells, was reduced in spleens from prednisolone treated mdx mice,
while VBP15 showed no decrease in B cells.
C. Spleen CD4þ T cell numbers were significantly decreased in prednisolone
treated mdx spleens, but not by VBP15 treatment.
D. Activation of mdx splenocyte T cells by concavalin A was impaired
by prednisolone, but not impaired by VBP15 treatment. Values are
mean  SEM. (Pred, prednisolone; (A) n  12, (B–D) n ¼ 3–5;  p  0.05,

p < 0.005).

reduced activated CD4þCD25þ cells (p ¼ 0.01), while VBP15 did
not. Taken together, these ﬁndings suggest VBP15 modulates
inﬂamed mdx immune systems towards a WT state, while
prednisolone treatment leads towards an immunocompromised
state.
VBP15 shows a superior side effect proﬁle compared to
pharmacological glucocorticoids
Stunted growth is a signiﬁcant side effect of chronic prednisone
use in children (Avioli, 1993; Wolthers & Pedersen, 1990). In our
pre‐symptomatic mdx study, prednisolone treatment signiﬁcantly stunted the growth of young mice (Fig 6A). After 5 weeks of
treatment, mdx mice receiving prednisolone were signiﬁcantly
shorter (8.6  0.4 cm) than vehicle (9.1  0.3 cm, p < 0.001). No
signiﬁcant reduction in body length was observed for any VBP15
dose.
Chronic treatment with glucocorticoids negatively affects
bone growth and development, and can cause osteoporosis
(Bircan et al, 1997; Manolagas & Weinstein, 1999). Tibia length
was measured to determine if VBP15 inhibited bone growth
(Fig 6B). Vehicle mdx mice had tibia lengths of 15.9  0.3 mm,
while prednisolone signiﬁcantly decreased this to 14.8  0.5 mm
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(p < 0.005). VBP15, however, did not affect tibia length at any
concentration. MicroCT was performed on femurs to examine
bone density and structure (Fig 6C). Comparison of vehicle,
prednisolone and the highest VBP15 dose showed prednisolone
to signiﬁcantly reduce trabecular thickness (p < 0.005) compared to vehicle, while VBP15 did not. Prednisolone thus
demonstrated side effects to bone not observed with VBP15
treatment.
We have previously reported deleterious effects of prednisone
on increased ﬁbrosis in mdx hearts (Sali et al, 2012). In both
pre‐clinical trials (pre‐symptomatic and adult), we examined
cardiac and skeletal muscle for measures of ﬁbrosis. In the pre‐
symptomatic trial (Fig 6D–F), prednisolone caused a signiﬁcant
elevation of heart mass ratios over vehicle (5.9  0.6 vs.
5.4  0.4, p < 0.05), indicative of cardiac hypertrophy. No
increase was present in VBP15 groups. Histologically, clear
ﬁbrosis was evident in 50% of young (8 weeks) prednisolone‐
treated hearts compared to 0% of all other groups. Histological
analyses of skeletal muscle (gastrocnemius) also showed
increased ﬁbrosis in prednisolone‐treated mice (8.1  2.2%,
p < 0.05) compared to vehicle‐treated (4.2  1.8%), VBP15‐
treated (3.5  1.2% at 30 mg/kg), and WT (2.0  0.5%) mice
(Supporting Information Fig 2C–E). In the adult trial, cardiac
ﬁndings were consistent with the pre‐symptomatic trial (Fig 6G
and H). Here as well, prednisolone treatment increased ﬁbrosis
and mass ratios of mdx hearts, while VBP15 did not.

DISCUSSION
Development of mechanisms to improve muscular dystrophy in
the absence of detrimental hormonal effects will substantially
improve DMD patient medical care, could provide a therapy for
dystrophies with no current treatment, and could improve care
of diverse chronic inﬂammatory disorders. Here, we describe the
development, mechanisms and effects of a novel drug that
dissects and optimizes several sub‐activities of classic glucocorticoids (Fig 7), demonstrating it is possible to treat muscular
dystrophy in the absence of growth, hormonal and immunosuppressive side effects. For one sub‐activity, we show VBP15
has protective physicochemical effects on the plasma membrane, protecting cells from injury and promoting membrane
repair. This sub‐activity is likely to be particularly important in
DMD where disease pathogenesis is clearly linked to membrane
instability and myoﬁbre injury. For another, we show that a key
anti‐inﬂammatory activity, inhibition of TNFa‐induced NF‐kB,
is retained by VBP15. We further show that this mechanism
occurs through protein–protein interactions of the VBP15
ligand‐activated GR, independently of DNA binding, GRE
activation, or upregulation of inhibitory transcripts. We have
previously shown that NF‐kB activation is among the earliest
histological features of DMD neonates (Chen et al, 2005;
Porter et al, 2002, 2003), years before symptoms appear. This,
coupled with the results of our blinded mdx pre‐clinical data
here, suggests that very early treatment of DMD patients
with VBP15 may prevent or delay the onset of some clinical
symptoms. Finally, the well‐documented and extensive side
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Figure 6. VBP15 lacks the side effects of current glucocorticoid regimens in vivo.
A. Prednisolone treatment stunted the growth of developing mice in comparison to both vehicle and VBP15 groups. Representative photographs (A) and
quantitation of body length (A0 ) are provided.
B. Bone lengths were reduced upon prednisolone treatment. X-rays (B) of mouse tibias illustrate size differences (scale bars ¼ 2 mm). Quantitation shows a
significant decrease in tibia length (B0 ).
C. MicroCT imaging analysis of femur revealed a significant decrease in trabecular thickness (C0 ) for prednisolone treated mice.
D–F. Increases in cardiac fibrosis and heart mass were detected in prednisolone treated mice, suggestive of cardiac damage as a side effect lacking for VBP15.
Sirius red staining of cardiac muscle shows increased fibrosis in prednisolone-treated mice, but not VBP15 mice. Representative images (D) and digital
quantitation of fibrosis (E) are provided. To the right of the image panel is a higher magnification image from the area outlined in box. (F) Heart mass ratios
were increased by prednisolone but not by VBP15.
G,H. In adult mdx mice as well, increases in cardiac fibrosis (G) and heart mass (G) were observed with prednisolone treatment but not VBP15 treatment. In adult
mdx vehicle mice, an expected disease- and age-related increase in fibrosis over WT is seen. Values are mean  SEM. (n  12 per group for (A,B,E,F); n  5 for
(C,G,H);  p < 0.05,   p < 0.005,    p < 0.0005).

effect proﬁles of glucocorticoids, inclusive of immunotoxicity,
growth stunting and effects on pituitary function, were not
seen with VBP15 at doses up to nine times prednisolone
dosing. These properties provide us with a new mechanistic
proﬁle with which to approach both patient therapy and
scientiﬁc questions regarding inﬂammation, signaling and
disease mechanisms.

EMBO Mol Med (2013) 5, 1569–1585

Steroidal compounds are multi‐mechanistic by nature and
display physicochemical effects on the plasma membrane (Rhen
et al, 2003; Shivaji & Jagannadham, 1992). We ﬁnd VBP15 and
prednisolone differ in their effects on membranes, with VBP15
treatment protecting live cells from laser‐induced injury.
Membrane‐stabilization is a property that is analogous to
poloxamer 188, Mitsugumin 53 or cromolyn sodium, which
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Figure 7. Working model of VBP15 and prednisone drug mechanism sub‐activity proﬁles. Steroidal compounds such as glucocorticoids (prednisone) and
D-9,11 compounds (VBP15) are multi-potent drugs. Through dissecting the sub-activities of these compounds, we find that: (1) VBP15 reduces inflammation but
does not show the immunosuppressive impairment of lymphocyte viability and function observed for prednisone. (2) Within an environment of plasma
membrane disruption, VBP15 helps to promote resistance to and repair of injuries, while prednisone can exacerbate membrane injury. (3) Inside cells, both
compounds bind to and activate the GR to potently inhibit inflammatory NF-kB signaling through protein–protein interactions. (4) Though they both bind to the
GR, prednisone causes strong induction of hormonal GRE controlled promoter elements, while VBP15 eliminates or greatly reduces these effects.

operate through varying mechanisms and show beneﬁcial
effects on dystrophin deﬁcient dog and mouse muscle in vivo
(Marques et al, 2008; Townsend et al, 2010; Weisleder
et al, 2012). Membrane‐stabilizing effects of VBP15, but not
prednisolone, are consistent with increases in speciﬁc force
observed for VBP15 but not for prednisolone. VBP15 effects on
membrane stability could be explained by altered compression
of phospholipid head groups within the membrane, altered ion
balances (Howard et al, 2011), altered membrane or vesicular
fusion (Shivaji & Jagannadham, 1992), or altered oxidative
stress at the plasma membrane (Howard et al, 2011; Kavanagh
& Kam, 2001; Marques et al, 2008; Saija et al, 2001). With
membrane integrity and repair becoming of increasing importance in muscle (Bansal et al, 2003; Jaiswal et al, 2007),
cardiovascular (Chase et al, 2009), neurodegenerative (Bazan
et al, 2005) and airway (Gajic et al, 2003) disorders,
physicochemical properties of VBP15 will be an intriguing area
of investigation moving forward.
Chronic treatment with glucocorticoids (prednisone, deﬂazacort) is the current standard of care for DMD, yet
glucocorticoids are well‐known to induce muscle atrophy
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pathways via FOXO1, stunt the growth of paediatric patients,
and can suppress the immune system which plays an important
role in myoﬁbre repair cycles. Thus, clinical improvements in
DMD patients treated with glucocorticoids may be the sum
balance of beneﬁcial anti‐inﬂammatory effects and deleterious
pathways. Both in vitro and in vivo data presented here
are consistent with this model. In mdx mice, we ﬁnd the net
balance of prednisolone treatment increases normalized
strength, however at the same time it stunts the growth of
mice resulting in lower maximal strength, is immunosuppressive, and increases the presence of muscle damage. We, as well
as others in recent reports (Bauer et al, 2009), also ﬁnd that
prednisolone increases cardiac ﬁbrosis in mdx mice. Comparable
examination of cardiac ﬁbrosis in glucocorticoid treated DMD
patients has not been examined directly in the literature,
however recent anecdotal cardiac MRI reports show substantial
ﬁbrosis, suggesting this may be an intriguing area of investigation moving forward, with a possibility to develop more “heart
healthy” treatments. VBP15 however does not stunt the growth
of mice, shows no evidence of splenocyte immunotoxicity, and
does not increase muscle ﬁbrosis in skeletal or cardiac muscle. In
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the absence of these side effects, VBP15 increases strength,
increases absolute and speciﬁc force measures and decreases
muscle inﬂammation. A comparison of VBP15 and prednisolone
mechanistic proﬁles in the context of these results has several
implications. One, stunted growth appears to be a side effect of
glucocorticoid treatment in DMD as opposed to a mechanism of
efﬁcacy, as has been logically proposed in the past (Grounds &
Shavlakadze, 2011) by limiting body size to reduce muscle
workload. Here, we see dose‐dependent increases in mdx
strength in the absence of stunted growth, suggesting the
potential to increase patient strength without overt effects to
growth and development. Two, immunotoxicity is a potential
side effect of glucocorticoid treatment – not the primary cause of
efﬁcacy. This is supported by the failure of general immunosuppression to increase DMD patient strength (Griggs et al, 1993;
Kissel et al, 1993). Three, NF‐kB inhibition is shared by both
drugs, supporting our hypothesis that this is a shared pathway of
efﬁcacy. In further support of this, peptides or antibodies
targeting NF‐kB pathways beneﬁt mdx phenotypes (Grounds &
Torrisi, 2004; Peterson et al, 2011), while in contrast,
constitutive activation of NF‐kB causes severe muscle wasting
(Cai et al, 2004; Mourkioti et al, 2006). Finally, GRE transactivation appears to be disposable to efﬁcacy in DMD. As GRE‐
regulated genes have been implicated in a number of
glucocorticoid side effects, this is particularly exciting because
it provides a clear avenue by which to reduce harsh side effect
proﬁles currently limiting the use of these widely applicable
drugs. Indeed, along with a reduction in GRE activity for
VBP15, we also see an absence of glucocorticoid side effects
in mdx mice. Importantly, efﬁcacy is maintained in the absence
of immunosuppression and overt hormonal effects to growth
and development, providing insight into mechanisms of
glucocorticoids in muscular dystrophy and demonstrating a
successful separation of pathways into dystrophy efﬁcacy and
side effects.
Exon skipping represents another promising line of therapeutic development for DMD (Hoffman et al, 2011). Short of gene
replacement, this may offer the greatest potential to alleviate
DMD because it aims to restore expression of disease‐causing
dystrophin deﬁciencies. However, isoforms induced by exon
skipping, as well as the mini‐gene dystrophin constructs
envisioned in gene therapy, are also expressed in Becker
muscular dystrophy (alleles of dystrophinopathy leading to
milder disease). In other words, both exon skipping and gene
therapy are expected to mitigate but not cure disease. We and
others ﬁnd exon skipping partially restores speciﬁc force deﬁcits
in mdx muscle, with ex vivo force contractions typically showing
approximately 20% increases over mdx controls (Aoki
et al, 2010; Dumonceaux et al, 2010). This likely represents
an upper limit to therapeutic strength increases, short of gene
replacement. We ﬁnd VBP15 treatment increases EDL speciﬁc
force as well, with 15 mg/kg producing 12 and 16% increases in
the two trials presented here. Currently, patients with Becker or
other milder muscle dystrophies are not routinely administered
prednisone (Johnsen, 2001) due to the unclear net balance of
detrimental versus beneﬁcial effects it would provide. Evidence
here suggests VBP15 could provide a novel therapy for Becker’s
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and other milder dystrophies, or serve as a valuable combination
therapy used with exon skipping to provide efﬁcacy through
independent mechanisms.
Currently, glucocorticoid regimens for DMD delay treatment
to avoid serious detriment, and many patients eventually
discontinue treatment as a result of side effects. A drug lacking
such harsh effects has the potential to change physicians’
treatment approaches since it would be more amenable to a
chronic treatment regimen, and would enable treatment during
pre‐symptomatic or late stages when many patients are not
taking prednisone. This rationale prompted us to change our
approach to mdx preclinical trial design for VBP15, and indeed
we saw clear efﬁcacy with an ablation of side effects to mdx
growth, bone and muscle. Intriguingly, by enabling treatment of
DMD at pre‐symptomatic ages, a strong rationale for neonatal
screening could be built to move forward towards a preventative
medicine approach to treatment, thereby improving the way we
diagnose and treat DMD patients.
International consensus has established the mdx mouse as the
model of choice for preclinical and proof‐of‐concept studies
because they represent the exact monogenic biochemical defect
present in DMD (Nagaraju & Willmann, 2009; Willmann
et al, 2009, 2012). However, mdx mice present a milder disease
than DMD, with peak severity from approximately 3–8 weeks
of age after which they recover substantially until advanced
ages. This prompts various strategies to exacerbate the mdx
phenotype. One strategy is to introduce additional mutations
which exacerbate disease onto the mdx background, examples
of which include the mdx:utrophin/ (Deconinck et al, 1997;
Grady et al, 1997b), mdx:adbn/ (Grady et al, 1999), mdx:
a7 integrin/ (Guo et al, 2006), mdx:PV/ (Raymackers
et al, 2003) and mdx:MyoD/ (Megeney et al, 1999) double
knockout models. These provide advantages through increased
disease severity and a differing array of symptoms, which allow
for more efﬁcient trials utilizing smaller sample sizes without
the added need of forced exercise protocols. Several groups
have thus utilized mdx:utrophin/ double transgenic mice
to successfully detect therapeutic efﬁcacy (Delﬁn et al, 2011;
Gehrig et al, 2012; Goyenvalle et al, 2010; Wakeﬁeld et al, 2000).
It is possible for a second mutation to introduce underlying
biochemical or biological differences however, for example
utrophin/ single transgenic mice have an increased susceptibility to seizures (Knuesel et al, 2002), along with altered
neuromuscular junction folding and altered acetyl choline
receptor density (Grady et al, 1997a), which could feasibly
affect neuromuscular disease outside of a direct consequence of
dystrophin deﬁciency (Willmann et al, 2009). Here, we chose to
use larger sample sizes of monogenic mdx mice to ensure that
the efﬁcacy parameters we measured were from phenotypes
directly resulting from dystrophin deﬁciency. To optimize our
trial designs, we adopted two strategies to measure mdx
phenotypes at points of increased severity, in one trial by
assaying young mice during natural peaks in disease severity,
and in the other by using forced exercise protocols in adult mice
to exacerbate disease. Through both strategies, we consistently
detect signiﬁcant mdx phenotypes and VBP15 efﬁcacy through
an improvement of mdx phenotypes towards wild type.
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Extension of VBP15 to other clinical disorders of membrane
instability and chronic inﬂammation will require further studies
and clinical development. Studies of VBP15 in animal models of
arthritis, asthma, multiple sclerosis and inﬂammatory bowel
diseases are currently underway. Through collaboration with the
Muscular Dystrophy Association Venture Philanthropy, and the
National Institutes of Health Therapeutics for Rare and
Neglected Disease (TRND) program, VBP15 is being actively
developed for DMD as the initial indication. Participation in
these programs has provided repeatability, efﬁcacy and safety
through independent trials both in vitro and in vivo. VBP15
shows favourable pharmacokinetic, ADME and metabolite
proﬁles (Reeves et al, 2013). Early safety studies by independent
groups suggest a single dose tolerance of at least 500 mg/kg in
mice, and a 28 day NOAEL of at least 100 mg/kg in mice, which is
more than twice the highest doses (30 and 45 mg/kg) used here
to show both efﬁcacy and a clear reduction in side effects in
comparison to prednisolone.
Our results demonstrate the successful separation of pathways providing efﬁcacy from side effects in muscular dystrophy.
The translation of these into model mice by treatment with a
novel, orally available drug, indicates that strength and
pathology phenotypes can be improved by treatment without
overt hormonal, growth or immunosuppressive effects. VBP15
merits further investigation for efﬁcacy in clinical DMD trials,
and is relevant to a diverse group of disorders through shared
inﬂammation or membrane injury molecular pathways. By
focusing on DMD as an initial indication, we beneﬁt from having
(i) models reproducing the ubiquitous molecular deﬁcit present
in all patients, and (ii) a homogenous patient population with
strong foundations providing national clinical trial support.
Movement into the clinic would improve treatment of human
disease, provide further mechanism insight and provide a
template for future drug development. With a molecular proﬁle
relevant to diverse disorders and DMD amenable to neonatal
screening, VBP15 may provide an excellent opportunity to
develop an Orphan disease therapy in a way that helps larger
groups of more complex disorders.

studies, cells were plated at 6E5 per well overnight, then serum starved
in six‐well plates. After 48 h, cells were drug treated for 6 h then lysed
for RNA. For ACTH studies, cells were plated at 1.3E6 per T25 ﬂask and
treated with drug. Media and drug were changed daily for 5 days, then
cells were counted and replated in six‐well plates. Twenty‐four hours
later, media was collected and cells lysed for RNA. ACTH secretion was
assessed by lumELISA (Calbiotech).

GR mutant assays
GRnull cells and the parental L929 ﬁbroblast line they were derived from
(Housley & Forsthoefel, 1989) were cultured in DMEM at 37°C. Protein
lysates were obtained from untreated cells using RIPA buffer, separated
on 4–15% PAGE gels, and transferred to nitrocellulose membranes,
which were immunoblotted with rabbit polyclonal anti‐GR (Santa
Cruz) and rabbit monoclonal anti‐GAPDH (Cell Signaling Technology),
followed by HRP‐secondary (Bio‐Rad). For assays of GRE and
inﬂammatory transcripts, cells were treated with drug for 24 h, then
stimulated with TNFa (1 ng/ml) for an additional 24 h, lysed for RNA,
and assayed by qPCR.
GRdim/dim mice (Reichardt et al, 1998) were obtained from the
Deutsches Krebsforschungszentrum (German Cancer Research Center).
GRdim/dim and wild type control (C57BL/6) mice were maintained in an
animal facility within IACUC guidelines under approved protocols.
Spleens were isolated and single cell suspensions generated through
homogenization and lysis of red blood cells using ACK lysis buffer (Lonza).
Splenocytes were treated with drug for 24 h, then stimulated with TNFa
(10 ng/ml) for another 24 h. RNA was extracted from splenocytes, with
analysis of GRE and inﬂammatory transcripts performed by qPCR.

Real‐time qPCR
cDNA was produced using the High Capacity cDNA Reverse Transcription
Kit (ABI). Transcript levels were analysed via TaqMan qPCR assays (LifeTech).
The following assays were used: Sgk1, Mm00441380_m1; Pomc,
Mm00435874_m1; Irf1, Mm01288580_m1; Cox2, Mm03294838_
g1; Nos2, Mm00440502_m1; Tnfa, Mm00443258_m1; Il1a,
Mm00439620_m1; Nfkbia, Mm00477800_g1; Il6, Mm00446190_m1.
qPCR was performed using TaqMan gene expression master mix and
18s rRNA as a normalization control (ABI).

Laser‐mediated wounding of live cells

MATERIALS AND METHODS
NF‐kB inhibition
C2C12 cells stably expressing an NF‐kB luciferase reporter were cultured
and assayed as described previously (Baudy et al, 2009). For GR antagonist
experiments, cells were treated with a constant concentration of drug
(1 mM) and increasing RU‐486 (Sigma) concentrations. In both experiments, cells were pretreated with drug for 1 h, stimulated with TNFa
(10 ng/ml) and assayed for luciferase activity 3 h later. H2K myoblasts
were cultured with gamma‐interferon at 33°C, and differentiated into
myotubes in six‐well plates with Matrigel at 37°C. Cells were plated 1E5
per well, treated with drug after 4 days of differentiation, induced with
TNFa 24 h later, and RNA harvested the following day.

C2C12 myoblasts were pretreated with drug in growth media for
15 min. Immediately following this, cells were wounded in imaging
media (Hank’s Balanced Salts, 10 mM HEPES, pH 7.4) containing drug
or equivalent vehicle, 2 mM Ca2þ and 2 mg/ml FM1‐43 dye (Molecular
Probes Inc.) at 37°C. Injuries were performed with a pulsed one‐photon
laser (‘Ablate’, Intelligent Imaging Innovations Inc.) and a custom
built Olympus IX81 microscope (Olympus America). Wounding was
performed with ablation power 116 in a 2  2 mm2 for all injuries.
Cells were imaged at 2 s intervals. Initial ﬂuorescence intensity was
measured and used to normalize subsequent time points. Fluorescence
intensity over time was measured within cell borders using SlideBook
5.0 (Intelligent Imaging Innovations Inc.).

Receptor binding assays
Pituitary cell assays
For pituitary cell line experiments, AtT‐20/D16v‐F2 cells (ATCC) were
maintained at 37°C, 5% humidity in DMEM with 10% FBS. In Sgk1
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The various steroid receptors (GR, MR, ER, AR and PR) were extracted
and incubated with a constant concentration of radiolabeled, high‐
afﬁnity ligand. Increasing concentrations of unlabeled VBP1, VBP3,
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VBP15 or high‐afﬁnity ligand controls (triamcinolone, spironolactone,
17‐b‐Estradiol, methyltrienolone or Promegestone) were added and
the percent binding of radiolabeled ligands determined to gauge the
afﬁnity of the unlabeled competitors for the steroid receptors.

Animal care and drug dosing
Two separate mdx trials were performed to provide repeatability as well
as contrasting treatment and phenotyping regimens. The larger “pre‐
symptomatic” mdx trial (78 mice total) is presented here as the primary
trial. WT (C57BL/10ScSnJ) and mdx (C57BL/10ScSn‐Dmd<mdx>/J)
mice were obtained from Jackson Laboratory (Bar Harbor, ME). All
experiments were conducted within IACUC guidelines under approved
protocols. PND15 was chosen as the trial start point because it was the
earliest age prednisolone could conﬁdently be safely administered
(Heine & Rowitch, 2009; Pinsky & Digeorge, 1965). At this point, mice
were divided into groups of equally matched body mass, which were
then blinded to both drug and genotype for subsequent phenotyping
and histology experiments. Treatment groups (n ¼ 12–14 per group)
consisted of WT vehicle, mdx vehicle, mdx VBP15 (5, 15 or 30 mg/kg),
and prednisolone (5 mg/kg). Mice received daily AM dosing via cherry
syrup vehicle at 1 ml per 1 g body weight. One mouse suffered a head
injury during phenotyping and was removed from subsequent
experiments. No adverse effects from drug treatment were observed.
Functional phenotyping was performed in 5‐week‐old mice. In vivo
imaging was performed in 6–7 week old mice. At 8 weeks of age,
terminal assays were performed and tissues harvested.
A separate ‘adult’ mdx trial (48 mice total) was performed during
lead compound identiﬁcation according to established standard
operating procedures. In this smaller, open‐label study, WT and mdx
mice (n ¼ 8 per group) received daily PM oral syrup vehicle,
prednisolone (5 mg/kg) or VBP15 (5, 15 or 45 mg/kg). All mice were
subjected to 30‐min run on horizontal treadmills at 12 m/min, twice a
week except during data collection to unmask the mild phenotype of
mdx mice. One death was recorded at VBP15 45 mg/kg body weight.
Mice were administered drug for 4 months starting at 6 weeks of age.

Motor function
At 5 weeks of age, mice in the neonate trial were assayed for motor
function via grip strength measurement. Strength was assessed daily
AM for 5 days using a grip strength meter (Columbus Instruments).
Data was interpreted as maximum daily values for each of ﬁve testing
days and averaged over the 5 days. Animals were acclimated for 1 week
prior to data collection.

glucose, 5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4 and
0.025 mM tubocurarine chloride) at 25°C bubbled with 95% O2 and
5% CO2. Contractile properties were measured ex vivo according to
established methods (Brooks & Faulkner, 1988) using a force apparatus
(model 305B, Aurora Scientiﬁc). Drop in force was measured after 10
lengthening contractions where each muscle was stretched over 10%
of its length.

Immunotoxicity studies
Peripheral blood was obtained via retro‐orbital bleed. Following
sacriﬁce, spleens and thymuses were harvested, weighed, and
processed to generate single cell suspensions of splenocytes and
thymocytes, respectively. Red blood cells in splenocytes and peripheral
blood were lysed with 3% acetic acid þ methylene blue (Stem Cell
Technologies). All leucocytes were quantiﬁed via haemocytometer. For
lympho‐phenotyping studies, splenocytes were stained for FACS with
FITC‐conjugated anti‐mouse CD4, PE‐conjugated anti‐mouse CD8, or
APC‐conjugated anti‐mouse B220 monoclonal antibodies (eBioscience). For CD4þ cell activation studies, splenocytes (5E5 per well)
were stimulated in RPMI 1640þ 10% FBS with 5 mg/ml concanavalin A
(Sigma–Aldrich) in 48‐well plates for 72 h at 37°C. Following
stimulation, cells were stained with FITC‐conjugated anti‐mouse
CD4 and APC‐conjugated anti‐mouse CD25 monoclonal antibodies
(eBioscience). All FACS analyses were conducted using a FACSCalibur
(BD Biosciences).

Histology
Parafﬁn cross‐sections were made of gastrocnemius, heart and
diaphragm muscles and stained with H&E. For gastrocnemius, images
were analysed in Image J software (NIH) according to previously
established methods (Spurney et al, 2009). For diaphragm, full tissue
sections were scored for inﬂammation by a trained veterinary
immunologist blinded to drug and genotype.
To assay ﬁbrosis, parafﬁn embedded muscles were cross‐sectioned
and stained with Sirius Red. Tissue was imaged with a 4 objective,
digital captures were made with Olympus software, and ﬁbrotic signal
quantiﬁed using Image J (NIH). Blood and background were removed
from blinded images to prevent false detection of tissue and percent
signals when threshold measurements were made during ImageJ
quantitative analysis. The percentage ﬁbrotic tissue was calculated
as area reaching Sirius Red positive thresholds divided by total tissue
area of the section.

X‐ray and microCT analysis of bone
Live imaging
Mice were anaesthetized with isoﬂurane, and cathepsin caged near‐
infrared imaging was performed on 6–8 mice per group as described
previously (Baudy et al, 2011). Brieﬂy, mice received intraperitoneal (IP)
injections of ProSense 680 (Perkin–Elmer) in PBS 24 h prior to imaging
within an Optix MX2 Imager (ART). Scans of uninjected mice were
performed to obtain baseline optical intensity measurements. Forelimb
and hindlimb measurements were made at 0.5 mm resolution and
analysed using Optiview software.

Ex vivo force contractions
At trial endpoint, EDL muscle was isolated from live anaesthetized mice
and placed in Ringer’s solution (137 mM NaCl, 24 mM NaHCO3, 1 mM
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Skeletons were harvested at trial endpoint and stored in 10% formalin.
X‐rays of tibias were obtained using a Cabinet X‐Ray System (Faxitron
Model 43855) with exposure at 50 kVp for 1.5 min. Magniﬁcation error
was calculated to be 0.02 mm. Images were scanned and tibia lengths
measured in Adobe Illustrator (v6.0) at 2400% zoom. Measurements of
the opposite tibia were also obtained physically with digital calipers
during dissection, with results in agreement between methods. MicroCT
analysis was performed on harvested femurs using a SkyScan 1172
MicroCT (Bruker, Belgium). Imaging was performed at 40 kV source
voltage, 250 uA source current, 295 ms exposure time, and 0.4° rotation
step, with a 0.5 mm aluminum ﬁlter. The imaging resolution size was
6.2 um. Three‐dimensional reconstructions were performed with
Skyscan NRecon and Dataviewer software. Trabecular bone was
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The paper explained
PROBLEM:
Glucocorticoids have been a mainstay in medicine since their
discovery over 60 years ago. They are powerful anti-inflammatory drugs used to treat a variety of conditions. However, due to a
complex mechanism profile, glucocorticoids also cause harsh
side effects such as brittle bones, muscle wasting, stunted
growth, adrenal suppression and weight gain. Patients and
doctors must therefore manage their net positive and negative
effects. This is of particular importance in some chronic or
paediatric disorders, where lifelong treatment is required and
patients must live with serious side effects. DMD is a lethal
genetic muscle disease for which glucocorticoids are the current
standard of care. Though glucocorticoids produce established
improvements in DMD patient outcome measures, their harsh
side effects dramatically affect patients’ quality of life. As a
result, physicians typically delay treatment in young children
until well after disease onset, and many families choose to stop
treatment even though there is no alternative currently available
in the clinic.

RESULTS:
The discovery that glucocorticoids possess several distinct subactivities provides an intriguing opportunity to produce drugs
that stimulate some of these activities while avoiding others. We
discover VBP15 as a novel, orally administered compound that

selected for analysis by a polygonal region of interest within the centre
of femur, starting at 70 slices (0.43 mm) proximal from the growth plate
and extending proximally 200 slices (1.23 mm) further. Trabecular
measurements were obtained from 3D analysis of the selected bone
using Skyscan CT‐analyzer software.

Statistical analyses for animal trials
Unless otherwise noted, normality of each measurement was tested via
Shapiro–Wilk normality test and normally distributed measurements
were compared between mdx treatment groups using one‐way ANOVA.
Measurements that were not normally distributed were compared with
a non‐parametric test. For efﬁcacy studies where mdx treatment
comparisons showed a signiﬁcant overall p‐value, post hoc linear tests
between each VBP15 dosage group and vehicle only were performed
and resulting p‐value adjusted for multiple testing by Sidak method. In
side effect assays where comparisons showed a signiﬁcant overall
p‐value, a Student’s t‐test was included between prednisolone and
vehicle groups for normally distributed measurements.

Author contributions
CRH designed, performed, and managed in vitro experiments
and the in vivo pre‐symptomatic trial, analysed data from both
trials and wrote the paper. JMD designed and performed
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shares specific anti-inflammatory effects with glucocorticoids
and also acts to stabilize cell membranes. Importantly, we also
find that VBP15 avoids specific activities established to cause
glucocorticoid side effects. Translating these findings into mice
with muscular dystrophy, we find that both preventive and
therapeutic regimens improve muscle strength and disease
pathology. Further, this efficacy is displayed in the absence of
hormonal, immunological and growth side effects seen in
glucocorticoid treated mice.

IMPACT:
There is a clear need for improved treatments in chronic
inflammatory diseases such as DMD, where safer drugs would
improve quality of life and provide justification for neonatal
screening. Data here confirms that small molecules can be
produced which separate the sub-activities of glucocorticoids
towards fulfilling this need. VBP15 is identified as the lead
compound, which is actively being developed towards the clinic.
Excitingly, proof-of-principle data shows that this compound
provides efficacy in mice with muscular dystrophy while
successfully eliminating important side effects. This provides
new insight into glucocorticoid sub-activities, and demonstrates
the potential to replace glucocorticoids as the standard of care
for DMD as well as other chronic inflammatory diseases.

immunology and other in vivo experiments, analysed/interpreted data, and is actively participating in preclinical VBP
compound development. QY performed several specialized
mouse imaging experiments. BCD performed dissection and
immunology experiments and is actively participating in
preclinical development. TH contributed to the design and
interpretation of experiments, and helped to perform in vivo
experiments. JHVM performed specialized in vivo muscle
physiology experiments. AS, BKM, and AP performed blinded,
in vivo experiments in the neonate trial. LS performed initial in
vitro injury experiments, provided training, and helped to
interpret data. JQ and KT performed blinded histopathology
experiments. SJ and SD designed and performed in vivo adult
preclinical trial experiments. OCR and CA designed and provided
X‐ray imaging, services, instruction and data processing for
X‐ray experiments. MC contributed to histology experiment
design and provided automated imaging, blinding and randomization. HGD performed statistical analyses for the two in vivo
trials. JKJ developed the live cell laser injury technology at
CNMC, provided the core equipment/services, provided funding, and participated in experimental design and analysis. EMC
and JMM are responsible for identifying and developing the
VBP compounds towards clinical development. EPH provided
mentorship, funding, input into experimental design, and helped
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